About: Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.35 (+2.62%)
ADAG NASDAQ Adagene Inc
Adagene Inc share price
ADAG price activity
Last Price
$2.350
Change (24hr)
0.06 USD (2.62%)
Volume
107.30K
Volume (4w avg)
-
Open
$2.26
Day Range
$2.25 - $2.54
Previous Close
$2.29
Last Trade
03 Nov, 9:00 pm GMT+0
Delayed
03 Nov, 9:00 pm GMT+0
ADAG price performance
Delayed
03 Nov, 9:00 pm GMT+0
ADAG details
ADAG Market Signals